Table of Contents: CATIE TreatmentUpdate - 2001


Canadian AIDS Treatment Information Exchange
Edited by: Sean Hosein

Jump to Table of Contents

TreatmentUpdate 120: August - Vol. 13, No. 4English  Françaises
 Depression linked to immune system decline in women

 La dépression contribuerait au déclin de l'immunité chez les femmes

HoseinSR
Researchers reported results on 765 HIV positive women who made regular visits to study clinics so that their health could be assessed. Researchers began recruitment between 1993 and 1995. Monitoring continued until March 2000. Thus, in some cases, researchers collected up to seven years of data.

 Carnitine for high triglycerides

 Carnitine contre les taux de triglycérides élevés

HoseinSR
Carnitine is an amino acid that is used to help move fatty substances to places inside cells where they can be burnt to release energy. The parts of a cell where this energy release takes place are called mitochondria. Carnitine can also act as an antioxidant and appears to play a role in maintaining the health of nerves and protecting the liver and kidneys from the toxicity of drugs. Carnitine exists in several forms; the two most commonly used are L-carnitine and L-acetyl-carnitine.

 Lipid-lowering drugs and changes to diet can make a difference

 Agents hypolipidémiants et modifications alimentaires contre les taux de lipides élevés

HoseinSR
Increased levels of lipids or fatty substances — triglycerides and cholesterol — in the blood of some people with HIV/AIDS (PHAs) who use highly active antiretoviral therapy (HAART) places them at increased risk for cardiovascular disease.

 Sexual dysfunction and HAART

 Dysfonction sexuelle et multithérapie

HoseinSR
The use of highly active antiretroviral therapy (HAART) can cause many side effects, as mentioned in our report on nevirapine. One possible side effect of HAART that is not usually mentioned is sexual dysfunction. There's not much information on this problem, in part because people in clinical trials of HIV/AIDS drugs are not usually questioned about sexual dysfunction. As well, both research subjects and data collectors may not feel comfortable talking about this issue.

 Immune booster used to fight drug-resistant herpes

 Un immunostimulant s'avère utile contre un virus herpétique résistant

HoseinSR
Unfortunately, cases of herpes that are resistant to these drugs are increasingly leaving doctors and their patients with few options. However, a group of doctors in New York recently reported the case of a person with AIDS who successfully recovered from drug-resistant herpes when he was treated with the immune booster Aldara (imiquimod).

 Effect of HAART on cervical growths

 Effet de la multithérapie sur les tumeurs cervicales

HoseinSR
The use of highly active antiretroviral therapy (HAART) has greatly improved survival rates among people with HIV/AIDS (PHAs). This occurs because HAART suppresses production of HIV, which allows the immune system to begin repairing itself. Unfortunately, the immune system does not become fully restored, perhaps because a low level of viral activity occurs even though HAART is used. As a result, the immune system is not 100% effective and some complications can still occur. This means that although the level of restored immunity may be enough to help PHAs resist many AIDS-related infections, it does not appear to be sufficient to prevent the development of some cancers.

 Switching to nevirapine — results after one year

 Traitement de remplacement par la névirapine – résultats un an plus tard

HoseinSR
Highly active antiretroviral therapy (HAART) has improved survival and decreased the chance of death from AIDS-related infections in people who can afford, adhere to, and tolerate the drug cocktails. The last point — tolerate — is important because HAART-users can experience a variety of side effects depending on the combination of drugs taken.

Table Of Contents

TreatmentUpdate 123: November/December - Vol. 13, No. 7
Can delavirdine substitute for ritonavir?; Hepatitis C treatment, HAART and side effects; Toxicity profile of HAART; Rosiglitazone for lipodstrophy?; Actos (pioglitazone); Focus on fat; Metformin — long-term results; Sugar blues and protease inhibitors; Glucose — from food to blood sugar; Lipodystrophy - introduction; Caution with nelfinavir and some lipid-lowering drugs; Trizivir approved in Canada;

TreatmentUpdate 122: October - Vol. 13, No. 6
Looking at soluble CD23 levels to predict lymphoma; Cidofovir for KS lesions; Can low-dose shark cartilage make Kaposi's sarcoma disappear?; Chemo and HAART extend survival with lymphoma; Encouraging news on lymphoma from France; AIDS and lymphoma; New formulation of ddI approved in Canada — Videx EC; Expanded access to tenofovir

TreatmentUpdate 121: September - Vol. 13, No. 5
SIDE EFFECTS - Andractim for HAART-associated breast enlargement; SIDE EFFECTS - Does efavirenz cause breast enlargement?; IMMUNE BOOSTERS - Interleukin-12 may be useful for hepatitis C; ANTI-HIV AGENTS - Study finds HIV subtly damages vision; ANTI-HIV AGENTS - Searching for the right dose of ritonavir-saquinavir; ANTI-HIV AGENTS - Different combinations of ritonavir-indinavir

TreatmentUpdate 120: August - Vol. 13, No. 4
Depression linked to immune system decline in women; Carnitine for high triglycerides; Lipid-lowering drugs and changes to diet can make a difference; Sexual dysfunction and HAART; Immune booster used to fight drug-resistant herpes; Effect of HAART on cervical growths; Switching to nevirapine — results after one year

TreatmentUpdate 119: July - Vol. 13, No. 3
Fosamax for HIV-related bone problems?; Indinavir and bones: Does thickness = strength?; Lipodystrophy — nukes vs. protease inhibitors; Spanish study looks at nevirapine's effect on the liver; Pesticides found in many ginseng supplements in the U.S.; Can ginseng help suppress HIV?; Large Italian study looks at when to start HAART;

TreatmentUpdate 118: June - Vol. 13, No. 2
Protease inhibitors and blood sugar problems; Indinavir - effect on sugar and insulin; Background on glucose — from food to blood sugar; Extra co-enzyme Q10 for statin-users?; Can vitamin E help people recover from hepatitis B?; Study examines link between low levels of zinc and survival; Zinc and the immune system;

TreatmentUpdate 117: May - Vol. 13, No. 1
Bone damage - more than just nukes involved; Australian study links nukes, lactic acid to bone loss;High levels of lactic acid in some users of HAART ;Nukes may be linked to hearing loss; Of power plants and energy shortages; German study finds whey protein supplement boosts antioxidants; Spanish doctors try switching therapy from month to month

TreatmentUpdate 115: February - Vol. 12, No. 11
St. John's wort found to lower nevirapine levels; Are deaths due to liver damage becoming more common?; St. John's wort extract found not helpful for hepatitis C; Canadian researchers study "immune healing"; Kaletra approved in Canada;

TreatmentUpdate 114: January - Vol. 12, No. 10
Some women may be at high risk for anal cancer; DHEA — Cautions and concerns; DHEA for depression?; Changes in DHEA levels in people taking anti-HIV therapy; DHEA — Background; Nukes linked to fat wasting; Triple nuke therapy — results after one year; Switching meds: from protease inhibitors to non-nukes

Copyright / Staff / How to Contact

ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2000. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.